# ADARx Pharmaceuticals

**Canonical:** https://apis.io/providers/adarx-pharmaceuticals/  
**Website:** https://www.adarx.com/  
**APIs profiled:** 8

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered at 5871 Oberlin Drive, San Diego, California, founded in 2019 and developing next-generation RNA therapeutics intended to control the expression of specific disease drivers with highly selective RNA-targeted medicines. Its proprietary platform spans RNA interference, RNA editing and targeted oligonucleotide delivery, engineered around compact, modular constructs the company says extend reach beyond the liver. The clinical pipeline is led by ADX-324 (onvuzosiran), an siRNA against prekallikrein now in the Phase 3 STOP-HAE study in hereditary angioedema, and ADX-038 (agazisiran), an siRNA against complement factor B in Phase 2 for IgA nephropathy and C3 glomerulopathy, geographic atrophy and paroxysmal nocturnal hemoglobinuria; earlier programmes include ADX-626 (factor XI, thrombosis), ADX-077 (obesity) and ADX-199 (amyloid-beta precursor protein, neurodegeneration), plus undisclosed extrahepatic CNS, immunology and oncology work. The company closed an oversubscribed 200 million dollar Series C in August 2023 co-led by Bain Capital Life Sciences and TCGX, and entered a collaboration and license option agreement with AbbVie in May 2025. ADARx runs no developer program and publishes no product API, no developer portal and no API documentation; the only machine-readable surfaces reachable without credentials are the WordPress REST content APIs behind www.adarx.com and stophae.com, both catalogued here.

## Kin Score — 32.1 / 100 (thin)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 32.1).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 60.6 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 16.8 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 33.1 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | partial |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (8)

- **ADARx Pharmaceuticals Clinics API** — The STOP-HAE trial-site (clinic) registry.
- **ADARx Pharmaceuticals Content API** — Press releases, publications and corporate pages.
- **ADARx Pharmaceuticals Embed API** — oEmbed provider and SEO head rendering.
- **ADARx Pharmaceuticals Index API** — Route discovery and site identity.
- **ADARx Pharmaceuticals Media API** — The site media library.
- **ADARx Pharmaceuticals People API** — Content authors registered on the site.
- **ADARx Pharmaceuticals Search API** — Cross-content search.
- **ADARx Pharmaceuticals Taxonomy API** — Categories, tags, taxonomies and post statuses.

## Security (2)

- **Adarx Pharmaceuticals Authentication** — http · 2 schemes
- **Adarx Pharmaceuticals Domain Security** — TLSv1.3 · DNSSEC · DMARC

## Tags

Company, biotechnology, biopharmaceuticals, rna-therapeutics, sirna, rna-editing, clinical-trials, rare-disease, drug-development, life-sciences, san-diego, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/adarx-pharmaceuticals/). Scores are computed from the provider's own public artifacts under a published rubric.